chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 68.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, SARS-CoV-2 test
Clinical narrative: COVID 19 treatment; COVID 19 treatment; This is a spontaneous report received from contactable reporter (Consumer or other non HCP). The reporter is the patient.  A 68-year-old female patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 16Feb2023 at 11:00 as dose 5 (booster), single (Batch/Lot number: unknown) at the age of 68 years, in left arm for COVID-19 immunisation; COVID-19 vaccine (COVID-19 VACCINE), as dose 1, single (Batch/Lot number: unknown), as dose 2, single (Batch/Lot number: unknown), as dose 3 (booster), single (Batch/Lot number: unknown) and as dose 4 (booster), single (Batch/Lot number: unknown) for COVID-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "COVID 19 treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) positive; (09Jun2023) positive, notes: testing positive again. Therapeutic measures were taken as a result of drug ineffective, COVID-19 which included Paxlovid from 19May2023 to 24May2023.  The information on the batch/lot number for BNT162b2, BNT162b2 omi ba.4-5 has been requested and will be submitted if and when received.
Sex: U
Vaccine: COVID19
Symptoms: Hyperthyroidism
Clinical narrative: My hyperthyroid symptoms appeared 10 days after my first Pfizer vaccine; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received BNT162b2 (BNT162B2), as dose 1, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: HYPERTHYROIDISM (medically significant), 10 days after the suspect product(s) administration, outcome "unknown", described as "My hyperthyroid symptoms appeared 10 days after my first Pfizer vaccine". Additional information: patient's hyperthyroid symptoms appeared 10 days after first Pfizer vaccine. Patient had been trying to control that ever since.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Interchange of vaccine products, Nasopharyngitis
Clinical narrative: Have used Pfizer (Comirnaty) and Moderna vaccines; Have used over-the-counter cold medicines ie Alka-Seltzer Power Max Gels; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A female patient received BNT162b2 (BNT162B2 NOS), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation; elasomeran (MODERNA COVID-19 VACCINE), as dose number unknown, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: INTERCHANGE OF VACCINE PRODUCTS (non-serious), outcome "unknown", described as "Have used Pfizer (Comirnaty) and Moderna vaccines"; NASOPHARYNGITIS (non-serious), outcome "unknown", described as "Have used over-the-counter cold medicines ie Alka-Seltzer Power Max Gels". Therapeutic measures were taken as a result of nasopharyngitis.  Additional information: Have used Pfizer (Comirnaty) and Moderna vaccines. Have used over-the counter cold medicines i.e Alka-Seltzer Power Max Gels. The case was not severe and did not need a prescription. Age is 74.  The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.
Sex: F
Vaccine: COVID19
Symptoms: Body height, Body height decreased, Condition aggravated, Discomfort, Gait disturbance
Clinical narrative: Marfan syndrome became more significant; Marfan syndrome became more significant; incredibly sick; hardly walk; curvature of spine/ significant scoliosis; lost weight; shrank/Body height decreased; uncomfortable for the next 2 days; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A female patient received BNT162b2 (BNT162B2), in 2022 as dose 3 (booster), single (Batch/Lot number: unknown) intramuscular for covid-19 immunisation. The patient's relevant medical history included: "Lyme Disease", start date: 2006 (ongoing); "Marfan syndrome" (ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, MANUFACTURER UNKNOWN), for covid-19 immunization; Covid-19 vaccine (DOSE 2, MANUFACTURER UNKNOWN), for covid-19 immunization. The following information was reported: MARFAN'S SYNDROME (medically significant), CONDITION AGGRAVATED (medically significant) all with onset 2022, outcome "unknown" and all described as "Marfan syndrome became more significant"; SCOLIOSIS (medically significant) with onset 2022, outcome "unknown", described as "curvature of spine/ significant scoliosis"; GAIT DISTURBANCE (medically significant) with onset 2022, outcome "unknown", described as "hardly walk"; ILLNESS (medically significant) with onset 2022, outcome "unknown", described as "incredibly sick"; WEIGHT DECREASED (non-serious) with onset 2022, outcome "unknown", described as "lost weight"; BODY HEIGHT DECREASED (non-serious) with onset 2022, outcome "unknown", described as "shrank/Body height decreased"; DISCOMFORT (non-serious) with onset 2022, outcome "unknown", described as "uncomfortable for the next 2 days". The patient underwent the following laboratory tests and procedures: Body height: (2022) Decreased; Weight: (2022) Lost. Clinical course: Previously she had not had spinal changes or anything  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Illness, Marfan's syndrome, Scoliosis, Weight, Weight decreased
Clinical narrative: Marfan syndrome became more significant; Marfan syndrome became more significant; incredibly sick; hardly walk; curvature of spine/ significant scoliosis; lost weight; shrank/Body height decreased; uncomfortable for the next 2 days; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A female patient received BNT162b2 (BNT162B2), in 2022 as dose 3 (booster), single (Batch/Lot number: unknown) intramuscular for covid-19 immunisation. The patient's relevant medical history included: "Lyme Disease", start date: 2006 (ongoing); "Marfan syndrome" (ongoing). The patient's concomitant medications were not reported. Vaccination history included: Covid-19 vaccine (DOSE 1, MANUFACTURER UNKNOWN), for covid-19 immunization; Covid-19 vaccine (DOSE 2, MANUFACTURER UNKNOWN), for covid-19 immunization. The following information was reported: MARFAN'S SYNDROME (medically significant), CONDITION AGGRAVATED (medically significant) all with onset 2022, outcome "unknown" and all described as "Marfan syndrome became more significant"; SCOLIOSIS (medically significant) with onset 2022, outcome "unknown", described as "curvature of spine/ significant scoliosis"; GAIT DISTURBANCE (medically significant) with onset 2022, outcome "unknown", described as "hardly walk"; ILLNESS (medically significant) with onset 2022, outcome "unknown", described as "incredibly sick"; WEIGHT DECREASED (non-serious) with onset 2022, outcome "unknown", described as "lost weight"; BODY HEIGHT DECREASED (non-serious) with onset 2022, outcome "unknown", described as "shrank/Body height decreased"; DISCOMFORT (non-serious) with onset 2022, outcome "unknown", described as "uncomfortable for the next 2 days". The patient underwent the following laboratory tests and procedures: Body height: (2022) Decreased; Weight: (2022) Lost. Clinical course: Previously she had not had spinal changes or anything  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Sex: U
Vaccine: UNK
Symptoms: No adverse event, Product preparation issue
Clinical narrative: dose that was given only contained the liquid vaccine component without the lyophilized vaccine component, with no reported adverse event; Initial information was received on 06-Jun-2023 regarding an unsolicited valid non-serious case received from a consumer/non-hcp.  This case involves a 6 months old and unknown gender patient who experienced dose that was given only contained the liquid vaccine component without the lyophilized vaccine component, with no reported adverse event while receiving vaccine diphtheria/tetanus/5 hybrid ac pertussis/IPV(vero)/HIB(PRP/T) vaccine [Pentacel (vero)].  The patient's past medical history, medical treatment(s), vaccination(s), concomitant medications and family history were not provided.   On 05-Jun-2023, the patient received 0.5 ml once dose 3 of suspect diphtheria/tetanus/5 hybrid ac pertussis/IPV(vero)/HIB(PRP/T) vaccine (lot number: UJ840AA, expiration date: 16-Feb-2024) via intramuscular route in the right thigh for Immunization (immunisation).  On 05-Jun-2023 the patient developed a non-serious event of "dose that was given only contained the liquid vaccine component without the lyophilized vaccine component, with no reported adverse event" (product preparation error) (unknown latency) following the administration of diphtheria/tetanus/5 hybrid ac pertussis/IPV(VERO)/HIB(PRP/T) vaccine.  It was reported "about a PENTACEL that was administered by a nurse to a pediatric patient. The dose that was given only contained the liquid vaccine component (DTAP-IPV component) without the lyophilized vaccine component. She also wanted to know what to do next. Gender was unable to report during the call."  No lab data reported.  Action taken: not applicable.  Outcome: Unknown for the event dose that was given only contained the liquid vaccine component without the lyophilized vaccine component, with no reported adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 75.0
Sex: F
Vaccine: TYP
Symptoms: Incorrect dose administered, Injection site discharge
Clinical narrative: there was a little bit of leakage when she administered typhim vi pfs with no reported adverse event; Initial information received on 08-Jun-2023 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves a 75 years old female patient who for whom there was a little bit of leakage when she was administered with vaccine typhoid VI polysaccharide vaccine [Typhim VI] with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.  Concomitant medications included Encephalitis Vaccine for Prophylactic vaccination (immunization).  On 07-Jun-2023, the patient received 0.5 mL dose 3 of suspect typhoid VI polysaccharide vaccine, solution for injection (batch number: V2A451M; expiry date: 24-Oct-2027) via intramuscular route in unknown administration site for Immunization.  On 07-Jun-2023 the patient developed a non-serious there was a little bit of leakage when she administered typhim vi pfs with no reported adverse event (incorrect dose administered) (same day latency) following the administration of typhoid VI polysaccharide vaccine.  It was reported, Nurse reported that there was a little bit of leakage when she administered TYPHIM VI PFS to a patient.  Action taken: not applicable.  At time of reporting, the outcome was Unknown for the event there was a little bit of leakage when she administered typhim vi pfs with no reported adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Sex: U
Vaccine: YF
Symptoms: Incorrect dose administered, Injection site discharge, No adverse event
Clinical narrative: she gave a patient the yellow fever vaccine and some leaked out with no reported adverse event; Initial information received  on 08-Jun-2023 regarding an unsolicited valid non-serious case received from a other health professional.  This case involves an unknown age and unknown gender patient who had she gave a patient the yellow fever vaccine and some leaked out with no reported adverse event after receiving vaccine yellow fever vaccine [yf-vax].  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date, the patient received a dose of suspect yellow fever vaccine Solution for injection, lot number, strength, expiration date not reported via unknown route in unknown administration site for Prophylactic vaccination (immunisation).  On an unknown date the patient developed a non-serious she gave a patient the yellow fever vaccine and some leaked out with no reported adverse event (incorrect dose administered) (unknown latency)   Action taken was not applicable.  Outcome: Unknown for the event she gave a patient the yellow fever vaccine and some leaked out with no reported adverse event.  This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the guidelines. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 1.0
Sex: F
Vaccine: HIBV
Symptoms: Expired product administered, Medication error, No adverse event
Clinical narrative: gave acthib vaccine to a patient in december that was expired in october with no reported adverse event; Initial information received on 08-Jun-2023 regarding an unsolicited valid  non-serious case received from a other health professional.  This case involves a 12 months old female patient to whom HIB (PRP/T) vaccine [ACT-HIB] given in december that was expired in october with no reported adverse event.  The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided.   On an unknown date in Dec-2022 , the patient was given 0.5 ml dose once (1X) of suspect HIB (PRP/T) vaccine, powder and solvent for solution for injection, (lot UJ589AA:  Expiry date: Oct-2022; strength not reported) via unknown route in unknown administration site for Immunization that was expired in october with no reported adverse event (expired product administered) (latency: same day).  Action taken : not applicable.  Outcome : Unknown.   This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Age: 83.0
Sex: M
Vaccine: COVID19-2
Symptoms: Arthritis, Bladder dysfunction, Chronic obstructive pulmonary disease, Condition aggravated, Dyspnoea
Clinical narrative: Tinnitus doubled in volume, digestive system shut down, bladder function shut down, COPD increased severly (very short of breath), weakness in use of legs, increase in pain from neuropathy of legs and hands, arthritis began in neck and both arms.
Age: 83.0
Sex: M
Vaccine: COVID19-2
Symptoms: Gastrointestinal disorder, Irritable bowel syndrome, Muscular weakness, Neuropathy peripheral, Pain in extremity
Clinical narrative: Tinnitus doubled in volume, digestive system shut down, bladder function shut down, COPD increased severly (very short of breath), weakness in use of legs, increase in pain from neuropathy of legs and hands, arthritis began in neck and both arms.
Age: 83.0
Sex: M
Vaccine: COVID19-2
Symptoms: Scan abdomen abnormal, Spondylitis, Tinnitus, Ultrasound Doppler abnormal, Urinary tract imaging abnormal
Clinical narrative: Tinnitus doubled in volume, digestive system shut down, bladder function shut down, COPD increased severly (very short of breath), weakness in use of legs, increase in pain from neuropathy of legs and hands, arthritis began in neck and both arms.
Age: 83.0
Sex: M
Vaccine: COVID19-2
Symptoms: Venous occlusion
Clinical narrative: Tinnitus doubled in volume, digestive system shut down, bladder function shut down, COPD increased severly (very short of breath), weakness in use of legs, increase in pain from neuropathy of legs and hands, arthritis began in neck and both arms.
Age: 65.0
Sex: F
Vaccine: COVID19-2
Symptoms: Alopecia, Body temperature decreased, Influenza like illness, Vomiting
Clinical narrative: temperature dip, throwing up, all flu like symptoms.  Lasted from 4pm til morning In the following months, i noticed handfuls of hair falling out.  Clumps of hair, not just individual strands.
Age: 14.0
Sex: F
Vaccine: MMR
Symptoms: Disorientation, Eye movement disorder, Flushing, Hypersomnia, Hyporesponsive to stimuli
Clinical narrative: The patient received MmR#2 shot and, after 20 minutes, became disoriented and slumped over in the passenger seat.  She was unable to answer simple questions and was repeating herself.  Her face was flushed, and her eyes were rolling in the back of her head. She was unable to stay awake.  She slept for over 18 hours and awoke with a migraine.
Age: 14.0
Sex: F
Vaccine: MMR
Symptoms: Migraine, Posture abnormal
Clinical narrative: The patient received MmR#2 shot and, after 20 minutes, became disoriented and slumped over in the passenger seat.  She was unable to answer simple questions and was repeating herself.  Her face was flushed, and her eyes were rolling in the back of her head. She was unable to stay awake.  She slept for over 18 hours and awoke with a migraine.
Sex: M
Vaccine: VARZOS
Symptoms: Pain in extremity
Clinical narrative: Arm Soreness; This non-serious case was reported by a pharmacist and described the occurrence of pain in arm in a male patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced pain in arm (Verbatim: Arm Soreness). The outcome of the pain in arm was resolved (duration 4 days).   The reporter considered the pain in arm to be related to Shingrix.     The company considered the pain in arm to be related to Shingrix.   Linked case(s) involving the same patient:  US2023AMR081796   Additional Information: GSK Receipt Date:09-JUN-2023 The patient thought he might have an infection in his arm. The follow-up could not be possible as no contact details were available. For tolerance to the 2nd dose, refer case US2023AMR081796.; Sender's Comments:  US-GSK-US2023AMR081796:Same patient, same reporter, second dose, different events
Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event, Product storage error
Clinical narrative: The vial was initially stored in refrigerator on 06-Mar-2023 and was administered on 12-Apr-2023; No adverse event; 10 patients received vaccine that was stored in the refrigerator past 30-day storage mark, from vaccine Lot AS7173B; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (10 patients received vaccine that was stored in the refrigerator past 30-day storage mark, from vaccine Lot AS7173B), PRODUCT STORAGE ERROR (The vial was initially stored in refrigerator on 06-Mar-2023 and was administered on 12-Apr-2023) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On 12-Apr-2023, the patient received fourth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 12-Apr-2023, the patient experienced EXPIRED PRODUCT ADMINISTERED (10 patients received vaccine that was stored in the refrigerator past 30-day storage mark, from vaccine Lot AS7173B). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (The vial was initially stored in refrigerator on 06-Mar-2023 and was administered on 12-Apr-2023) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (10 patients received vaccine that was stored in the refrigerator past 30-day storage mark, from vaccine Lot AS7173B), PRODUCT STORAGE ERROR (The vial was initially stored in refrigerator on 06-Mar-2023 and was administered on 12-Apr-2023) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (10 patients received vaccine that was stored in the refrigerator past 30-day storage mark, from vaccine Lot AS7173B) and PRODUCT STORAGE ERROR (The vial was initially stored in refrigerator on 06-Mar-2023 and was administered on 12-Apr-2023).    Concomitant medication details not reported by the reporter. Dosage text was reported as Unknown. Batch number was reported as 069H22a and AS7173B. Vial with batch number 069H22a was initially stored in refrigerator on 18-APR-2023 and vial with batch number AS7173B initially stored in refrigerator on 06-MAR-2023. Vial did not undergo temperature excursion. Treatment details was not reported by the reporter. This case contains information of 8th patient out of 10 patient.   This case was linked to US-MODERNATX, INC.-MOD-2023-728204 (Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-728204:Master case Patient no-1
Sex: U
Vaccine: COVID19
Symptoms: Expired product administered, No adverse event
Clinical narrative: No adverse event; Vaccines administered past the expiration date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccines administered past the expiration date) and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 060H21A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 11-Apr-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Apr-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccines administered past the expiration date). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccines administered past the expiration date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Vaccines administered past the expiration date).    No concomitant medications were reported. It was reported that as per the provider the vaccines were stored in a standard freezer (15°C to -25°C). Their temperatures were Max: -24C and Min: -23C. It was reported that Moderna COVID-19 Vaccine with Lot number: 060H21A was received on 27-Dec-2020 with expiration date as 28-Mar-2022 but the Date of administration was 11-Apr-2022 with doses of 13. Treatment information was not provided. This is case is for Patient 10 of 13 patients.   This case was linked to US-MODERNATX, INC.-MOD-2023-728240 (E2B Linked Report).   Most recent FOLLOW-UP information incorporated above includes: On 07-Jun-2023: Follow-up received and had no new information.; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-728240:Master Case(Patient 1)
Sex: U
Vaccine: COVID19-2
Symptoms: Expired product administered, No adverse event
Clinical narrative: no adverse event; Nurse administered expired dose of Moderna bivalent. Exp: 06Jun2023; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Nurse administered expired dose of Moderna bivalent. Exp: 06Jun2023) and NO ADVERSE EVENT (no adverse event) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 024H22A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 08-Jun-2023, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 08-Jun-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced EXPIRED PRODUCT ADMINISTERED (Nurse administered expired dose of Moderna bivalent. Exp: 06Jun2023). On an unknown date, the patient experienced NO ADVERSE EVENT (no adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Nurse administered expired dose of Moderna bivalent. Exp: 06Jun2023) and NO ADVERSE EVENT (no adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (no adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Nurse administered expired dose of Moderna bivalent. Exp: 06Jun2023).    Concomitant medication was not reported. Treatment medication was not reported.   Reporter did not allow further contact
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 2 vaccines  Moderna 4/17/21 lot# 045B21A;  Moderna 5/20/21 lot# 023C21A
Age: 95.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 2 vaccines Pfizer 7/8/21 lot# EW0186;  Pfizer 8/5/21 lot# Ew0181
Age: 78.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 2 vaccines Moderna 8/23/21 lot# 007B21A;  Moderna 9/28/21 lot# 045C21A
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after one dose Janssen
Age: 68.0
Sex: M
Vaccine: VARZOS
Symptoms: Extra dose administered
Clinical narrative: Extra Dose; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 68-year-old male patient who received Herpes zoster (Shingrix) (batch number CR5XF, expiry date 23-AUG-2025) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on 10th September 2019), Shingrix (received 2nd dose on 12th November 2019) and Zostavax (had shingles vaccine years ago and the patient meant they had Zostavax).   On 07-JUN-2023, the patient received the 3rd dose of Shingrix. On 07-JUN-2023, an unknown time after receiving Shingrix, the patient experienced extra dose administered (Verbatim: Extra Dose). The outcome of the extra dose administered was unknown.   Additional Information: GSK Receipt Date: 09-JUN-2023 The pharmacist reported the patient came into pharmacystating he had shingles vaccine years ago and wanted to get the Shingrix. The pharmacy thought that the patient meant he had Zostavax and pharmacy administered a dose of Shingrix. The pharmacy later found the documentation that the patient had received the two doses of Shingrix. The reporter did not have the lot number and expiration date information for the first two doses. The vaccine administration facility was the same as Primary Reporter. The reporter consented to follow up. The patient received 3rd dose of Shingrix, which led to extra dose administered.
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Hypoaesthesia, Paraesthesia
Clinical narrative: KNEE PAIN; NUMBNESS; TINGLING; This spontaneous report received from a patient concerned a female of unspecified age. The patient's weight, height, and medical history were not reported. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose, start therapy date were not reported for covid-19 prophylaxis. The batch number was not reported and has been requested. No concomitant medications were reported. On an unspecified date, the patient experienced knee pain, numbness, and tingling. Treatment medications (dates unspecified) included: diclofenac, and prednisone. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from tingling, and the outcome of knee pain and numbness was not reported. This report was non-serious.
Age: 1.0
Sex: U
Vaccine: COVID19-2
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse event; they gave the wrong concentration of the vaccine to children age group 6 months to 5 years; This spontaneous case was reported by an other health care professional and describes the occurrence of WRONG PRODUCT ADMINISTERED (they gave the wrong concentration of the vaccine to children age group 6 months to 5 years) and NO ADVERSE EVENT (No adverse event) in a 1-year-old patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 201L22A) for COVID-19 prophylaxis.     It was reported that the patient's caregiver did not report any relevant medical history, conditions, allergy, concomitant diseases, or risk factor (including any previous COVID-19 diagnosis).  Previously administered products included for Product used for unknown indication: Kinrix, MMRV and FLU [INFLUENZA VACCINE]. Past adverse reactions to the above products included No adverse event with FLU [INFLUENZA VACCINE], Kinrix and MMRV.    On 01-Jun-2023, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) .2 milliliter. On 01-Jun-2023, the patient experienced WRONG PRODUCT ADMINISTERED (they gave the wrong concentration of the vaccine to children age group 6 months to 5 years). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (they gave the wrong concentration of the vaccine to children age group 6 months to 5 years) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (they gave the wrong concentration of the vaccine to children age group 6 months to 5 years).    Concomitant drugs were not reported. It was reported that patient received vaccine from a dark pink with yellow box a dosage of 0.2 ml instead of blue cap with gray border since they have not received the vaccine before.  Treatment medications were not provided.  This case was reported for patient 2.   This case was linked to US-MODERNATX, INC.-MOD-2023-728512 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-728512:patient 01
Age: 4.0
Sex: U
Vaccine: COVID19-2
Symptoms: No adverse event, Wrong product administered
Clinical narrative: No adverse event; they gave the wrong concentration of the vaccine to children age group 6 months to 5 years; This spontaneous case was reported by an other health care professional and describes the occurrence of WRONG PRODUCT ADMINISTERED (they gave the wrong concentration of the vaccine to children age group 6 months to 5 years) and NO ADVERSE EVENT (No adverse event) in a 4-year-old patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. 201L22A) for COVID-19 prophylaxis.     It was reported that the patient's caregiver did not report any relevant medical history, conditions, allergy, concomitant diseases or risk factor (including any previous COVID-19 diagnosis).  Previously administered products included for Product used for unknown indication: HEPATITIS A VACCINE, FLU [INFLUENZA VACCINE], MEASLES, MUMPS AND RUBELLA VACCINE, VACCINE /PERTUSSIS/TETANUS/DIPHTHERIA/, HIB VACCINE and PNEUMOCOCCAL VACCINE CONJ 15V (CRM197). Past adverse reactions to the above products included No adverse event with FLU [INFLUENZA VACCINE], HEPATITIS A VACCINE, HIB VACCINE, MEASLES, MUMPS AND RUBELLA VACCINE, PNEUMOCOCCAL VACCINE CONJ 15V (CRM197) and VACCINE /PERTUSSIS/TETANUS/DIPHTHERIA/.    On 01-Jun-2023, the patient received first dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular) .2 milliliter. On 01-Jun-2023,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced WRONG PRODUCT ADMINISTERED (they gave the wrong concentration of the vaccine to children age group 6 months to 5 years). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (they gave the wrong concentration of the vaccine to children age group 6 months to 5 years) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Intramuscular), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for WRONG PRODUCT ADMINISTERED (they gave the wrong concentration of the vaccine to children age group 6 months to 5 years).    Concomitant drugs were not reported. It was reported that patient received vaccine from a dark pink with yellow box a dosage of 0.2 ml instead of blue cap with gray border since they have not received the vaccine before.  Treatment medications were not provided.  This case was reported for patient 1.   This case was linked to US-MODERNATX, INC.-MOD-2023-728517 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2023-728517:patient 2
Age: 88.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 2 vaccines Pfizer 4/7/21 lot# Ew0150;  Pfizer 4/28/21 Lot# Ew0162
Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 2 vaccines Pfizer 5/21/21 lot# EW0182;  Pfizer 6/11/21 lot# Ew0180
Age: 87.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 3 vaccines Moderna 2/25/21 lot# 010A21A;  Moderna 3/25/21 lot# 030A21A;  Moderna 12/8/21 Lot# 060H21A
Age: 81.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 3 vaccines 2/15/21 Moderna lot# 015M20A;  Moderna 3/15/21 lot# 002B21A;  Moderna 11/18/21 lot# 065F21A
Age: 55.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 2 vaccines Pfizer 3/18/21 Lot# ER2613;  Pfizer 4/8/21 lot# Ew0158
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 2 admissions Pfizer 3/8/21 Lot# EN6206;  Pfizer 3/29/21 lot# ER8732;  Pfizer 11/28/21 Lot# FG3527
Age: 73.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 2 vaccines Pfizer x2; Pfizer 6/3/21 lot# EW0179;  Pfizer 6/24/21 Lot# EW0179
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after one dose Janssen
Age: 64.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: breakthrough case admission after 2 vaccines Moderna 3/20/21 lot# 047A21A;  Moderna 4/17/21 lot# 043B21A
Age: 96.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 5 vaccines Moderna 1/14/21 lot# 012L20A;  Moderna 2/11/21 lot# 010M20A;  Pfizer 3/1/21 NO LOT #;  MOderna 10/1/21 no lOT#;  MOderna 12/1/21 lot# FJ8762
Age: 92.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 4 vaccines Moderna 1/28/21 lot# 028L20A;  Moderna 2/25/21 lot# 004M20A;  Moderna 11/10/21 lot# 033F21A;  MOderna 4/21/22 lot# FM9992
Age: 86.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test positive, Vaccine breakthrough infection
Clinical narrative: Breakthrough case admission after 2 vaccines Moderna 10/29/21 lot# 939904;  Moderna 11/22/22 Lot# 059F22A
Age: 59.0
Sex: M
Vaccine: COVID19
Symptoms: Acute myocardial infarction
Clinical narrative: ACUTE NON ST ELEVATION MI
Age: 33.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Hypotension, Hypoxia, Symptom recurrence
Clinical narrative: HYPOTENSION ACUTE HYPOXEMIC RESPIRATORY FAILURE HYPOXEMIA 6/9/2022,  11/24/2022,  12/31/2022,  11/28/2022,  11/26/2022,  12/20/2022,  3/11/2023  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Age: 52.0
Sex: F
Vaccine: COVID19
Symptoms: Dysphonia, Laryngitis, Laryngitis viral, No adverse event
Clinical narrative: I had no reaction to the vaccine. In 03/2023, I was diagnosed with chronic laryngitis that lasted about 3 weeks. I saw a doctor and was advised that it was viral and treated as it was viral. I had chronic laryngitis in 12/2021 too. As of today, I am feeling better but my voice is still not the same.
Age: 81.0
Sex: F
Vaccine: COVID19-2
Symptoms: Acute respiratory failure, Respiratory failure
Clinical narrative: ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE ACUTE ON CHRONIC HYPERCAPNIC RESPIRATORY FAILURE
Age: 1.25
Sex: M
Vaccine: PNC15, PNC15
Symptoms: Needle issue
Clinical narrative: Vaccine leaked out around needle port connection
Age: 1.25
Sex: M
Vaccine: PNC15, PNC15
Symptoms: No adverse event, Poor quality device used, Syringe issue
Clinical narrative: Vaccine leaked out around needle port connection
Age: 68.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Pulmonary embolism, Symptom recurrence
Clinical narrative: ACUTE HYPOXEMIC RESPIRATORY FAILURE ACUTE PULMONARY EMBOLISM 12/1/2022  &   12/14/2022  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: Obstructive sleep apnoea syndrome
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE OBSTRUCTIVE SLEEP APNEA
Age: 5.0
Sex: F
Vaccine: DTAPIPV, MMRV
Symptoms: Rash, Rash erythematous, Rash pruritic, Rash vesicular
Clinical narrative: Patient developed an erythematous vesicular rash localized to her anterior trunk, flanks, and bilateral hips 24 hours after receiving her routine vaccinations (MMRV and DTaP-IPV) at her 5 year WCC on 6/9/2023. Parent reports the rash was initially faint and became more prominent within 48 hours. Patient reports the rash is itchy. Parent treated with OTC antihistamine which he reports did offer some relief. At her OV on 6/12/2023 parent reports the rash is improving in appearance. Parent reports no associated sx including fever, URI sx, sore throat, vomiting, and diarrhea. No known sick contacts.
Age: 78.0
Sex: F
Vaccine: COVID19-2
Symptoms: Embolic stroke
Clinical narrative: ACUTE STROKE DUE TO EMBOLISM OF UNSPECIFIED ARTERY
Age: 79.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Hypoxia
Clinical narrative: ACUTE RESPIRATORY FAILURE ACUTE HYPOXEMIC RESPIRATORY FAILURE HYPOXIA
Age: 86.0
Sex: M
Vaccine: PPV
Symptoms: Chills, Loss of personal independence in daily activities, Pain in extremity, Peripheral swelling
Clinical narrative: sore swollen arm, chills, could not perform daily duties.
Age: 61.0
Sex: M
Vaccine: COVID19-2
Symptoms: Unevaluable event
Clinical narrative: ACUTE MI
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Neuropathy peripheral
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE NEUROPATHY
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Pulmonary embolism
Clinical narrative: ACUTE PULMONARY EMBOLISM
Age: 0.5
Sex: F
Vaccine: COVID19-2
Symptoms: Incorrect dose administered, Wrong product administered
Clinical narrative: The patient was given 0.2ml dose from the Pink cap vial of Moderna. This was the incorrect vial and dosage. Should have been given 0.25 ml from the blue cap vial of Moderna. This was the patients first dose of Moderna COVID vaccine. Patient will need to restart the series per PCP.
Age: 37.0
Sex: F
Vaccine: TD
Symptoms: Injected limb mobility decreased, Pain in extremity
Clinical narrative: Patient reports that she had the vaccine on 06/05/23 following a cut on her right hand. Friday the pain peaked in the left arm and she continues to have pain and limited range of motion in the left arm. She was advised to be evaluated by a provider and appointment was scheduled for mid-day 06/13/23.
Age: 14.0
Sex: M
Vaccine: MNQ
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Menveo administered too close to first dose. No signs/symptoms reported.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: COVID-19, Chest discomfort, Cold sweat, Cough, Dizziness
Clinical narrative: 2/27/23  I woke up with a sore throat.  I then became cold, clammy and lightheaded.  I did not feel like I was with it.  I began feeling a tightness in my chest and a headache that was unbelievable. I took a Tylenol. I went to Urgent Care and tested positive for COVID. I was prescribed Paxlovid and began taking it that day. I continued with a cough for two weeks.  I took 2 at home COVID tests that were positive and then one that was negative.
Age: 59.0
Sex: F
Vaccine: COVID19
Symptoms: Feeling abnormal, Feeling cold, Headache, Oropharyngeal pain, SARS-CoV-2 test positive
Clinical narrative: 2/27/23  I woke up with a sore throat.  I then became cold, clammy and lightheaded.  I did not feel like I was with it.  I began feeling a tightness in my chest and a headache that was unbelievable. I took a Tylenol. I went to Urgent Care and tested positive for COVID. I was prescribed Paxlovid and began taking it that day. I continued with a cough for two weeks.  I took 2 at home COVID tests that were positive and then one that was negative.
Age: 55.0
Sex: M
Vaccine: COVID19-2
Symptoms: Coagulopathy, Symptom recurrence
Clinical narrative: COAGULOPATHY, UNSPECIFIED TYPE 1/16/2023  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS
Age: 61.0
Sex: F
Vaccine: PNC20
Symptoms: Pain, Pain in extremity
Clinical narrative: Pain down legnth of left arm, exacerbated by exertion or lifting weight.
Age: 17.0
Sex: M
Vaccine: HEP
Symptoms: Wrong product administered
Clinical narrative: Hepatitis B was given instead of Meningitis B
Age: 49.0
Sex: F
Vaccine: COVID19
Symptoms: Injected limb mobility decreased, Injection site mass, Injection site nodule, Injection site pain, Pain in extremity
Clinical narrative: Three after receiving the second vaccine you developed a knot on my arm like the vaccine did not go anywhere. I called to the doctor to find out what I needed to do or if I should come in. I was advised to put a warm compress on my arm, use Epsom salt, massage my arm to help get the vaccine to disperse throughout my system. Subsequently every dose of the COVID-19 vaccine after the second dose has made the area get bigger, my arm is even more painful. I made an appointment to see my doctor, I cannot lift my arm, if I touch the mass accidentally the pain is horrible. I will be going in for an ultrasound to find out if they can see what is going on in the mass.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: Myocardial ischaemia
Clinical narrative: DEMAND ISCHEMIA
Age: 0.58
Sex: F
Vaccine: HIBV
Symptoms: Expired product administered
Clinical narrative: On May 17th, 2023 patient came into the clinic for her 6 month well child visit and received multiple vaccines one of which was an Expired vaccine, was given in the right thigh. There was no treatment needed for this, no injury occured.
Age: 70.0
Sex: M
Vaccine: COVID19
Symptoms: Deep vein thrombosis
Clinical narrative: TYPE 2 MI ACUTE DVT OF LEFT LEG, UNSPECIFIED VEIN
Age: 57.0
Sex: M
Vaccine: COVID19
Symptoms: Cerebrovascular accident, Obstructive sleep apnoea syndrome
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE OBSTRUCTIVE SLEEP APNEA ACUTE STROKE, UNSPECIFIED TYPE AND ARTERY
Age: 7.0
Sex: M
Vaccine: COVID19
Symptoms: Chest pain, Cough, Dyspnoea, Inflammation, Influenza
Clinical narrative: He had the flu and was having trouble breathing. He also had a fever, chest pain, and a terrible cough. He was prescribed Tamiflu. Now his airway is restricted anytime there is inflammation. We are still dealing with this at this time.
Age: 7.0
Sex: M
Vaccine: COVID19
Symptoms: Influenza virus test positive, Obstructive airways disorder, Pyrexia
Clinical narrative: He had the flu and was having trouble breathing. He also had a fever, chest pain, and a terrible cough. He was prescribed Tamiflu. Now his airway is restricted anytime there is inflammation. We are still dealing with this at this time.
Age: 22.0
Sex: M
Vaccine: COVID19-2
Symptoms: Dyspnoea, Paraesthesia
Clinical narrative: Approximately 10 minutes following vaccine administration, the patient complained of tingling in his fingers and shortness of breath. The pharmacist asked the patient if they needed emergency services and checked for signs and symptoms of allergic reaction. The pharmacist called for emergency services. The patient walked out of the building with the EMTs.
Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: Acute respiratory failure, Chronic respiratory failure, Hypersomnia, Hypoxia, Neuropathy peripheral
Clinical narrative: PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE HYPERSOMNIA W SLEEP APNEA ADULT OBSTRUCTIVE SLEEP APNEA NEUROPATHY ACUTE HYPERCAPNIC RESPIRATORY FAILURE CHRONIC HYPERCAPNIC RESPIRATORY FAILURE ACUTE ON CHRONIC HYPERCAPNIC RESPIRATORY FAILURE RESPIRATORY FAILURE, UNSPECIFIED ACUITY HYPERCAPNIC RESPIRATORY FAILURE, UNSPECIFIED ACUITY HYPOXIA 1/26/2023  --  RECURRENCE OF HOSPITALIZATION WITH SAME SYMPTOMS